研究目的
To compare changes in choroidal hyperpermeability after half-energy photodynamic therapy (PDT) and intravitreal ranibizumab in the treatment of chronic central serous chorioretinopathy (CSC).
研究成果
The study concluded that half-energy PDT is more effective than intravitreal ranibizumab in reducing choroidal hyperpermeability in chronic CSC, with a significant correlation between treatment efficacy and reduction in choroidal hyperpermeability. The novel image analysis method provided a quantitative assessment of choroidal hyperpermeability changes.
研究不足
The study's limitations include the potential for error in the image analysis method due to differences in brightness and contrast between pre- and post-treatment ICGA images. The method requires further refinement to account for these variations.
1：Experimental Design and Method Selection:
A randomized, controlled trial comparing half-energy PDT versus intravitreal ranibizumab for chronic CSC was conducted. Post-hoc analysis was performed to quantify changes in choroidal hyperpermeability using a commercially available image analysis program.
2：Sample Selection and Data Sources:
Patients diagnosed with chronic or recurrent central serous chorioretinopathy were included.
3：List of Experimental Equipment and Materials:
Adobe? Photoshop? CS6 for image analysis, Heidelberg Retina Angiography for ICGA, and Cirrus OCT for retinal thickness measurement.
4：Experimental Procedures and Operational Workflow:
Treatment efficacy was evaluated at 3 months post-treatment. ICGA images were analyzed using Adobe Photoshop to quantify choroidal hyperpermeability changes.
5：Data Analysis Methods:
Integrated gray scale values per area in subtracted images were used for analysis. Statistical analysis was performed using PASW version 18.0.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
